Patents by Inventor Jim A. Wright

Jim A. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6417169
    Abstract: This invention relates to oligonucleotides complementary to the IGF-II genes which modulate tumor cell growth in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: July 9, 2002
    Assignee: Genesense Technologies Inc.
    Inventors: Jim A. Wright, Aiping H. Young, Yoon S. Lee
  • Publication number: 20020004488
    Abstract: The present invention provides a method of modulating the malignant properties of a cell in a human or other mammal by contacting a neoplastic cell with a growth modulating amount of an expressible nucleic acid sequence for ribonucleotide reductase R1 of the mammal. The present invention also provides and uses a growth modulating amount of the ribonucleotide reductase R1 protein or biologically active peptide to modulate the malignant properties of a cell in a human or other mammal. The method provides for a generally elevated expression of the R1 component of mammalian ribonucleotide reductase. The expressible nucleic acid sequence can be in the form of a vector for gene therapy.
    Type: Application
    Filed: September 24, 1998
    Publication date: January 10, 2002
    Inventors: JIM A. WRIGHT, AIPING H. YOUNG
  • Patent number: 6121000
    Abstract: Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: September 19, 2000
    Assignee: Genesense Technologies, Inc.
    Inventors: Jim A. Wright, Aiping H. Young
  • Patent number: 5998383
    Abstract: A synthetic antisense oligonucleotide comprising at least seven nucleotides or nucleotide analogues having a sequence complementary to the mRNA sequence of ribonucleotide reductase dimeric protein component R2 including SEQ ID Nos:1-102 is disclosed. A synthetic antisense oligonucleotide comprising at least seven nucleotides or nucleotide analogues having a sequence complementary to the mRNA sequence of ribonucleotide reductase dimeric protein component R1 including SEQ ID Nos:103-161 is also disclosed. The invention also discloses pharmaceutical compositions including the synthetic antisense oligonucleotides of the present invention and methods of using the antisense oligonucleotides to modulation proliferative cells including neoplastic cells.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: December 7, 1999
    Inventors: Jim A. Wright, Aiping H. Young